Journal article
State-related alterations of gene expression in bipolar disorder: A systematic review
K Munkholm, M Vinberg, M Berk, LV Kessing
Bipolar Disorders | Published : 2012
DOI: 10.1111/bdi.12005
Abstract
Objective: Alterations in gene expression in bipolar disorder have been found in numerous studies. It is unclear whether such alterations are related to specific mood states. As a biphasic disorder, mood state-related alterations in gene expression have the potential to point to markers of disease activity, and trait-related alterations might indicate vulnerability pathways. This review therefore evaluated the evidence for whether gene expression in bipolar disorder is state or trait related. Methods: A systematic review, using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline for reporting systematic reviews, based on comprehensive database searches f..
View full abstractGrants
Funding Acknowledgements
The study was supported by the Lundbeck Foundation and by the Danish Council for Independent Research/Medical Sciences. MV has served as a consultant for Eli Lilly & Co., AstraZeneca, Servier, and Janssen-Cilag. MB has received grant/research support from the Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, the Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvayand, and Wyeth; and has served as a consultant to Astra Zeneca, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmith Kline, Janssen Cilag, Lundbeck, and Servier. LVK has served as a consultant for Bristol-Myers Squibb, Eli Lilly & Co., Lundbeck, AstraZeneca, Pfizer, Wyeth, Servier, and JanssenCilag. KM has no conflicts of interest to disclose.